logo
This Hand Roll Bar From a Sushi Master Is Opening in Highland Park

This Hand Roll Bar From a Sushi Master Is Opening in Highland Park

Eater2 days ago

Los Feliz sushi spot Sogo Roll Bar is expanding with a second location along a busy stretch of York Boulevard in Highland Park. Opening on June 4 in the former Holcomb space, the restaurant will debut with the same menu of hand and cut rolls, donburi, and starters, including cucumber salad, as the original location. Sogo Roll Bar comes from a partnership between David Gibbs and Kiminobu Saito of renowned Valley sushi restaurant Sushi Note, and Sarah Dietz and Dustin Lancaster, the industry veterans behind Los Angeles bars that include Bar Covell, L&E Oyster Bar, and Real Charmer.
Although Dietz wasn't actively looking to expand Sogo, the opportunity arose after Holcomb closed in April. During the two-month flip, the restaurant's interior was updated with green Japanese stucco walls and maroon heron print Gucci wallpaper. Simon St. James of New Made LA designed lighting for the space, while Ellery Stoneware created custom earth-tone serveware. A wooden bar runs the length of the dining room, flanked by a handful of tables, and a patio that faces the street outside seems ideal for sake and snacks.
Fans of Sogo's original location will find familiar favorites on the Highland Park menu, including the roll sets with fish like snapper, yellowtail, and salmon. Shareable starters include spicy tuna crispy rice, black cod, salmon sashimi, and baked crab crispy rice. Larger donburis are topped with a choice of raw fish like salmon or albacore, black cod, or cucumber and avocado. While the roll sets offer an easy way to try a diverse array of fish, individual rolls are also available with toro, spicy tuna, unagi, and more.
Alongside the food menu, Sogo also serves sake, wine, beer, and non-alcoholic beverages. Sakes are divided into three categories to guide customers, like 'light and refreshing,' 'savory and interesting,' and 'fruity and funky.' While Sogo's Los Feliz location didn't open with a liquor license, the drinks program is a major focus in Highland Park. 'We're really trying to have a bit more focus on being a drinking and snack destination, as well as full meals,' Dietz says. Sushi is what the restaurant may be best known for, but she hopes locals in the neighborhood will pop by for a glass of sake and snacks before a show or dinner.
Sogo's arrival in Highland Park brings an all-day sushi option to a neighborhood with a small number of Japanese restaurants. One of the only other sushi restaurants in the area, Ichijiku Sushi, is only open for dinner on weekdays, with late afternoon hours on the weekends. Sogo is also focused on offering hand rolls at a price point where people can be regulars, with most sets falling into the $30 range. 'Raw fish is never going to be cheap price point, but we really try to ensure that it's a price point that you can be comfortable eating at,' Dietz says.
Even before opening, Dietz says that neighbors are looking forward to the restaurant's arrival. 'A neighbor was walking their dog down the street a couple weeks ago, and I told her it was going to be a hand roll bar,' she says. 'She screamed out loud in excitement.'
Sogo Roll Bar opens in Highland Park at 5535 York Boulevard, Los Angeles, CA 90042 on June 4. It will be open Monday to Thursday from 12 p.m. to 9 p.m., and Friday and Saturday from 12 p.m. to 9 p.m.
Sign up for our newsletter.
5535 York Blvd, Los Angeles, CA 90042, ,

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Japan's ispace tries lunar touchdown again with Resilience lander
Japan's ispace tries lunar touchdown again with Resilience lander

Yahoo

time42 minutes ago

  • Yahoo

Japan's ispace tries lunar touchdown again with Resilience lander

By Kantaro Komiya TOKYO (Reuters) -Japanese company ispace is set to try the lunar touchdown of its uncrewed spacecraft again on Friday two years after its failed inaugural mission, in a bid to become the first company outside the United States to achieve a moon landing. Tokyo-based ispace hopes to join U.S. firms Intuitive Machines and Firefly Aerospace, which have accomplished commercial landings amid an intensifying global race for the moon that includes state-run missions from China and India. Resilience, ispace's second lunar lander, is expected to touch down on Mare Frigoris, a basaltic plain about 900 km (560 miles) from the moon's north pole, at 4:17 a.m. Friday local time (1917 GMT Thursday) following an hour-long descent from lunar orbit, according to the company. In 2023, ispace's first lander crashed into the moon's surface due to inaccurate recognition of its altitude. Software remedies have been implemented, while the hardware design is mostly unchanged in Resilience, the company has said. Resilience carries a four-wheeled rover built by ispace's Luxembourg subsidiary and payloads worth a total of $16 million, including scientific instruments from Japanese firms and a Taiwanese university. If the landing is successful, the 2.3-metre-high lander and the microwave-sized rover will begin 14-day exploration activities until the arrival of a freezing-cold lunar night, including capturing images of regolith, the moon's fine-grained surface material, on a contract with U.S. space agency NASA. Later on Friday, ispace will host a press conference about the outcome of the mission, according to the company. Shares in ispace more than doubled earlier this year on growing investor hopes for the second mission, before calming in recent days. Resilience in January shared a SpaceX rocket launch with Firefly's Blue Ghost lander, which took a faster trajectory to the moon and touched down successfully in March. Intuitive Machines, which last year marked the world's first touchdown of a commercial lunar lander, made its second attempt in March but the lander Athena ended on its side on the lunar surface just as in the first mission. Japan last year became the world's fifth country to achieve a soft lunar landing after the former Soviet Union, the U.S., China and India, when the national Japan Aerospace Exploration Agency (JAXA) achieved the touchdown of its SLIM lander, yet also in a toppled position. Despite President Donald Trump's proposed changes to the U.S. space policy, Japan remains committed to NASA's Artemis moon program, pledging the involvement of Japanese astronauts and technologies for future lunar missions. Including one in 2027 as part of the Artemis program, ispace plans seven more missions in the U.S. and Japan through 2029 to capture increasing demands for lunar transportation.

Japan Organic Dairy Market Competition & Forecasts to 2030, with Profiles of Meiji, KANEKA, Arla Foods Ingredients, Saputo, Fonterra Co-Operative, Amiksa, Abel & Cole, Cedar Grove Cheese & more
Japan Organic Dairy Market Competition & Forecasts to 2030, with Profiles of Meiji, KANEKA, Arla Foods Ingredients, Saputo, Fonterra Co-Operative, Amiksa, Abel & Cole, Cedar Grove Cheese & more

Yahoo

timean hour ago

  • Yahoo

Japan Organic Dairy Market Competition & Forecasts to 2030, with Profiles of Meiji, KANEKA, Arla Foods Ingredients, Saputo, Fonterra Co-Operative, Amiksa, Abel & Cole, Cedar Grove Cheese & more

The Japanese Organic Dairy Market is poised for growth due to rising health consciousness and preference for organic products. Disposable incomes, urbanization, and sustainability trends further drive demand. Challenges include high costs, but functional dairy gains popularity, signaling market potential. Japanese Organic Dairy Market Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Japan Organic Dairy Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to Japanese Organic Dairy Market was valued at USD 1.67 Billion in 2024, and is expected to reach USD 2.45 Billion by 2030, rising at a CAGR of 6.60%. This growth is largely attributed to rising health awareness among Japanese consumers who increasingly prefer organic and natural food products, including dairy, as a way to avoid synthetic additives and hormones. Higher disposable incomes and urbanization have improved access to premium organic dairy items, while sustainability-driven consumer behavior further supports market expansion. The emphasis on environmentally friendly farming practices and stricter food safety regulations enhances consumer trust in organic labeling. Additionally, the widespread availability of organic dairy across modern retail and online platforms boosts accessibility, appealing to consumers across various age groups. These combined factors are steadily propelling the growth of organic dairy consumption throughout Japan. Key Market Drivers: Rising Health-Conscious Population Across the Region A growing health-conscious population in Japan is a major contributor to the expansion of the organic dairy market. As more consumers recognize the long-term health benefits of avoiding synthetic additives, hormones, and antibiotics, the demand for organic dairy products continues to rise. These products are widely perceived as cleaner, safer, and more nutritious, aligning with a lifestyle focused on wellness and preventive healthcare. Educational outreach and media coverage have further raised public awareness about the adverse effects of conventional dairy production. Younger consumers and urban residents, in particular, are shifting toward organic food choices. According to the Statistics Bureau of Japan, there are approximately 18.47 million individuals under the age of 15, accounting for about 14.6% of the population-a segment highly influential in shaping future consumer behavior. As wellness trends gain traction, organic dairy is becoming a staple for health-focused diets, accelerating market growth. Key Market Challenges: High Product Cost High product pricing remains a major hurdle for the Japan organic dairy market, restricting its appeal among price-sensitive consumers. The elevated cost is largely due to the more expensive inputs required for organic farming, such as premium feed and extended production cycles. Additionally, compliance with stringent organic standards increases operational expenses, which are passed on to end consumers in the form of higher retail prices. Limited production volumes and scale inefficiencies further contribute to the cost burden. These dynamics can deter budget-conscious shoppers despite a growing interest in organic options. Without broader affordability, the market risks slow penetration outside premium consumer segments. To address this challenge, manufacturers and retailers must focus on improving operational efficiencies, raising awareness about the health and environmental benefits of organic dairy, and potentially leveraging government support or subsidies to narrow the price gap with conventional dairy products. Key Market Trends: Rising Popularity of Functional Dairy Products A key trend shaping the Japan organic dairy market is the increasing consumer interest in functional dairy products that offer health benefits beyond basic nutrition. Products formulated to support digestion, immunity, and metabolic health are gaining traction. This demand is particularly evident among aging demographics and health-aware consumers seeking dietary solutions that complement preventive healthcare. Items such as probiotic yogurts, fortified milks, and fermented drinks are seeing rising popularity. For example, Morinaga Milk Industry launched the Puresu fermented beverage in April 2024 under Japan's Food with Function Claims (FFC) system, promoting benefits like reduced fatigue and belly fat. Similarly, Meiji introduced the Eye and Sleep W Support drink containing crocetin to aid sleep and eye health. These developments illustrate a growing market segment focused on functional, organic dairy products aligned with consumer health goals and wellness trends. Key Market Players: Meiji Holdings KANEKA Arla Foods Ingredients Group Saputo Inc. Fonterra Co-Operative Group Amiksa Abel & Cole Limited Cedar Grove Cheese Horizon Organic Dairy Rumiano Key Attributes: Report Attribute Details No. of Pages 82 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $1.67 Billion Forecasted Market Value (USD) by 2030 $2.45 Billion Compound Annual Growth Rate 6.6% Regions Covered Japan Report Scope: In this report, the Japan Organic Dairy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: Japan Organic Dairy Market, By Product Type: Butter Cheese Milk Yogurt Others Japan Organic Dairy Market, By Packaging Type: Pouches Tetra-Packs Bottles Cans Others Japan Organic Dairy Market, By End User: Residential Commercial Japan Organic Dairy Market, By Sales Channel: Supermarkets/Hypermarkets Convenience Stores Online Others Japan Organic Dairy Market, By Region: Hokkaido & Tohoku Chubu Chugoku Kyushu Rest of Japan For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Japanese Organic Dairy Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio

Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management
Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management

Yahoo

timean hour ago

  • Yahoo

Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management

Series D led by Lightstone Ventures and ClavystBio, supported by leading global syndicate of new and existing investors; Additional venture debt funding led by HSBC Funds to advance ATX101 Phase 2b registration trial of post-surgical pain management in total knee replacement patients, data anticipated in Q4 2025 Joe Zakrzewski joins as Chairman of Allay Board of Directors Maruishi Pharmaceutical, Allay's partner in Japan, expands license territory to S. Korea and Taiwan SAN JOSE, Calif., June 05, 2025--(BUSINESS WIRE)--Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the completion of a $57.5M Series D financing round with leading global investors. Lightstone Ventures and ClavystBio co-led the Series D financing with participation by existing investors NEA, Arboretum Ventures, Vertex Growth, Vertex Ventures Healthcare, and Brandon Capital. New investors joining the round were IPD Capital, EDBI and SGInnovate, and HSBC Innovation Banking also provided additional venture debt financing to the Company. Allay also announced that Joe Zakrzewski, an experienced pharmaceutical executive, has been appointed Chairman of the Board of Directors, and Anselm Tan of ClavystBio will also join Allay's board, associated with the financing. Allay Therapeutics' Japanese partner Maruishi Pharmaceutical has expanded the territory of its license agreement to include South Korea and Taiwan, in addition to Japan. As part of the amendment to the license, Maruishi has also made an additional investment in Allay as part of the Series D financing. Maruishi is currently conducting a Phase I/II multi-center open-label safety study of ATX101 in Japan. Proceeds from the financing supports the Company's Phase 2b registration trial evaluating ATX101 for the treatment of post-surgical pain following total knee replacement (TKA) surgery and advances Allay's ultra-sustained platform of products for other unmet needs after painful surgeries. ATX101 is a novel investigational analgesic designed to provide extended pain relief after surgery, reducing the need for opioids and improving patient recovery. "Lightstone Ventures is pleased to be joined by a strong syndicate of biotechnology and medical device investors in the U.S. and Asia to support Allay with this fundraise to advance the Company's platform of products into pivotal clinical development. The Company is enrolling its Phase 2b registration trial ATX101 in the US for TKA surgeries and are expecting early completion of this trial in the coming months," stated Mike Carusi, Managing Partner at Lightstone Ventures. "It is rewarding to see Allay, which Lightstone Singapore helped to incubate alongside our partners at the Foundry, continue to grow and prosper." "With our recent breakthrough therapy designation (BTD) by FDA and constructive Type B meeting discussions held in March 2025, we have a clear roadmap to complete the ATX101 development program in TKA and are looking at additional indications and unmet needs in orthopedics, plastic surgery, anesthesiology and other soft tissue surgeries," stated Adam Gridley, President & CEO of Allay Therapeutics. "We believe the ATX platform of products driven by our teams in Singapore and the U.S. can help improve patient outcomes, reduce opioid use and improve function more rapidly than currently available therapies." "We are proud to support Allay as they advance best-in-class non-opioid solutions for patients suffering from pain and poor recovery outcomes after surgery. Allay exemplifies ClavystBio's mission to accelerate life sciences technologies from Singapore to the world," said Anselm Tan, Digital Health & MedTech Lead, ClavystBio. "ATX101 is one of several offerings in a pipeline driven by Singapore's R&D excellence, a strong collaboration among international teams, and a global syndicate of investors." Allay's Phase 2b registration trial of 200 participants undergoing total knee arthroplasty (replacement, or TKA surgery) is being conducted at multiple U.S. sites. The trial was initiated in February 2025 and is a three-arm, randomized, controlled study evaluating treatment with ATX101 1,500 mg versus placebo and a bupivacaine active comparator. A prior dose-ranging Phase 2b trial achieved clinically meaningful durable treatment effects with ATX101 versus standard-of-care bupivacaine based on pain intensity out to four weeks, with less use of opioids and meaningful improvement in functional activities up to 60 days following surgery. Based on those prior results, Allay's ATX101 product has received Breakthrough Therapy designation from the FDA. Results from the registration trial will be available in the fourth quarter of 2025 and a Phase 3 trial is planned for 2026. About Joe Zakrzewski:Mr. Zakrzewski has over 30 years of leadership experience in the biotechnology and pharmaceutical industry and has founded a number of biotechnology companies and been an inventor on numerous patents. He currently serves on the Board of Directors of multiple public & privately held companies. During his operating career he was Chairman and CEO of Amarin Pharmaceuticals, a Venture Partner with Orbimed, Chairman, President & Chief Executive Officer of Xcellerex, a privately held company sold to GE Healthcare, and COO of Reliant Pharmaceuticals, a privately held company sold to GSK plc. Prior to this, Mr. Zakrzewski served in various executive roles including global leadership for Business Development at Eli Lilly & Company. He received a BS in Chemical Engineering and an MS in Biochemical Engineering from Drexel University, and an MBA in Finance from Indiana University. About Lightstone VenturesLightstone Ventures is a global venture capital firm investing in biotech and medtech companies pioneering big ideas poised to transform patient outcomes. We were founded in 2012 to empower visionary entrepreneurs with the resources and operational guidance necessary to bring their innovative therapeutics and technologies to the patients who need them most. Our investment team has led deals resulting in 19 acquisitions and 20 initial public offerings over the last two decades. The firm has offices in Boston, Mass., Portola Valley, Calif., and Dublin, Ireland. For more information, please visit About ClavystBioClavystBio is a life sciences investor and venture builder established by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with innovators, entrepreneurs and founders to launch and grow global companies from Singapore. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing startups together, we foster a vibrant and supportive community. Since our inception in 2022, ClavystBio has committed over US $220 million in investments in the life sciences sector. For more information, please visit About ATX101ATX101 is a novel investigational configuration of an approved, well-characterized, validated intracellular sodium ion channel blocker, bupivacaine, and a biopolymer that has been designed to provide weeks of pain relief following total knee arthroplasty (TKA, or replacement), a common orthopedic surgery. ATX101 has a high density of drug within its small footprint to allow for ultra-sustained analgesia. It is placed in minutes at the end of standard surgery to deliver its analgesic effect over weeks before eventually dissolving into water and carbon dioxide. The simple procedure does not require specialized training and is intended to replace the existing complex mix of analgesic products used for shorter-term pain management in the post-surgical setting. ATX101 is an investigational product that has not been approved by the U.S. Food and Drug Administration. About Allay TherapeuticsAllay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. Our proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates to deliver pain relief within a targeted site over weeks: an order of magnitude greater than the longest-lasting pain treatments currently available. Our platform and vision were shaped by The Foundry incubator and Lightstone Venture's Singapore Fund. Allay unites a dynamic, global team of entrepreneurs, scientists, clinicians and innovators in the San Francisco Bay Area and Singapore. Learn more at View source version on Contacts For further details, please contact:InvestorsAdam Mediaallay@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store